It was found that addition of anti-VEGF monoclonal antibody (Bevacizumab) to the traditional chemoradiation treatment of NPC apparently delayed the progression of distant metastasis [128]. This evidence concerns the gene VEGFA and nasopharyngeal carcinoma.